In the BioHarmony Drug Report Database
Pexidartinib
Turalio (pexidartinib) is a small molecule pharmaceutical. Pexidartinib was first approved as Turalio on 2019-08-02. It is used to treat giant cell tumor of tendon sheath in the USA. The pharmaceutical is active against mast/stem cell growth factor receptor Kit and macrophage colony-stimulating factor 1 receptor. In addition, it is known to target tyrosine-protein kinase Lck, NT-3 growth factor receptor, vascular endothelial growth factor receptor 2, vascular endothelial growth factor receptor 1, receptor-type tyrosine-protein kinase FLT3, and cyclin-dependent kinase 19. Turalio’s patents are valid until 2038-07-24 (FDA).
Trade Name
|
Turalio |
|---|---|
Common Name
|
pexidartinib |
ChEMBL ID
|
CHEMBL3813873 |
Indication
|
giant cell tumor of tendon sheath |
Drug Class
|
Tyrosine kinase inhibitors |
Image (chem structure or protein)